Repository logo
  • English
  • Català
  • Čeština
  • Deutsch
  • Español
  • Français
  • Gàidhlig
  • Italiano
  • Latviešu
  • Magyar
  • Nederlands
  • Polski
  • Português
  • Português do Brasil
  • Srpski (lat)
  • Suomi
  • Svenska
  • Türkçe
  • Tiếng Việt
  • Қазақ
  • বাংলা
  • हिंदी
  • Ελληνικά
  • Српски
  • Yкраї́нська
  • Log In
    New user? Click here to register. Have you forgotten your password?
Repository logo
  • Communities & Collections
  • Browse UWCScholar
  • English
  • Català
  • Čeština
  • Deutsch
  • Español
  • Français
  • Gàidhlig
  • Italiano
  • Latviešu
  • Magyar
  • Nederlands
  • Polski
  • Português
  • Português do Brasil
  • Srpski (lat)
  • Suomi
  • Svenska
  • Türkçe
  • Tiếng Việt
  • Қазақ
  • বাংলা
  • हिंदी
  • Ελληνικά
  • Српски
  • Yкраї́нська
  • Log In
    New user? Click here to register. Have you forgotten your password?
  1. Home
  2. Browse by Author

Browsing by Author "Xulu Bheki"

Now showing 1 - 1 of 1
Results Per Page
Sort Options
  • Loading...
    Thumbnail Image
    Item
    Investigation of the coordination chemistry, biomolecular interactions, and cytotoxicity of heterocyclic carboxamide manganese(II) complexes
    (Wiley-VCH GmbH, 2025) Moabelo Koena; Meyer Mervin; Tsaulwayo Nokwanda; Xulu Bheki
    For the past few decades, platinum-based compounds notably cisplatin have been the most commonly used in metal-based anti-cancer treatment.[1,2] Despite the success of cisplatin, it has several drawbacks such as side effects, poor solubility, and acquired drug resistance, thus limiting its efficacy. [3,4] These negative attributes of cisplatin have germinated research interests in the design and development of alternative nonplatinum metallo-drugs such as ruthenium, iridium, osmium, palladium, and manganese. [5–7] Compared to the extensive reports on noble metals such as ruthenium and palladium, there are few reports on these of manganese compounds as anticancer agents. [8]

DSpace software copyright © 2002-2025 LYRASIS

  • Cookie settings
  • Privacy policy
  • End User Agreement
  • Send Feedback